EGFR first- and second-generation TKIs-there is still place for them in <i>EGFR</i>-mutant NSCLC patients.

"Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2018.10.06). The series “Targeted Therapy and Non-Small Cell Lung Cancer: A New Era?” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare."

"Funding: Work in Dr. Rosell’s laboratory is partially supported by a grant from La Caixa Foundation , a Marie Skłodowska-Curie Innovative Training Networks European Grant ( ELBA No. 765492 ), an Instituto de Salud Carlos III grant ( RESPONSE, PIE16/00011 ) and a Spanish Association against Cancer (AECC) grant ( PROYE18012ROSE ). The work of Niki Karachaliou and Jillian Wilhelmina Paulina Bracht in Pangaea Oncology is supported by a Marie Skłodowska-Curie Innovative Training Networks European Grant ( ELBA No. 765492 )."